JOP20230040A1 - تركيبات مستقرة تتألف من جسم مضاد egfr/c-met ثنائي النوعية - Google Patents
تركيبات مستقرة تتألف من جسم مضاد egfr/c-met ثنائي النوعيةInfo
- Publication number
- JOP20230040A1 JOP20230040A1 JOJO/P/2023/0040A JOP20230040A JOP20230040A1 JO P20230040 A1 JOP20230040 A1 JO P20230040A1 JO P20230040 A JOP20230040 A JO P20230040A JO P20230040 A1 JOP20230040 A1 JO P20230040A1
- Authority
- JO
- Jordan
- Prior art keywords
- met antibody
- stable formulations
- bispecific egfr
- pharmaceutical compositions
- formulations consisting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1406—Septums, pierceable membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070440P | 2020-08-26 | 2020-08-26 | |
| PCT/IB2021/057802 WO2022043900A1 (en) | 2020-08-26 | 2021-08-26 | Stable formulations comprising a bispecific egfr/c-met antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230040A1 true JOP20230040A1 (ar) | 2023-02-23 |
Family
ID=80352835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0040A JOP20230040A1 (ar) | 2020-08-26 | 2023-02-23 | تركيبات مستقرة تتألف من جسم مضاد egfr/c-met ثنائي النوعية |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20220064307A1 (https=) |
| EP (1) | EP4204456A4 (https=) |
| JP (1) | JP2023540025A (https=) |
| KR (1) | KR20230057400A (https=) |
| CN (1) | CN116194485A (https=) |
| AR (2) | AR123340A1 (https=) |
| AU (1) | AU2021333882A1 (https=) |
| BR (1) | BR112023003373A2 (https=) |
| CA (1) | CA3192630A1 (https=) |
| CR (1) | CR20230102A (https=) |
| EC (1) | ECSP23013655A (https=) |
| IL (1) | IL300895A (https=) |
| JO (1) | JOP20230040A1 (https=) |
| MX (1) | MX2023002367A (https=) |
| PE (1) | PE20231370A1 (https=) |
| TW (1) | TWI907491B (https=) |
| WO (1) | WO2022043900A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
| WO2024003837A1 (en) | 2022-06-30 | 2024-01-04 | Janssen Biotech, Inc. | Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer |
| AU2024287954A1 (en) * | 2023-07-07 | 2026-01-22 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Egfr/c-met bispecific binding protein and use thereof |
| WO2025079020A1 (en) | 2023-10-12 | 2025-04-17 | Janssen Biotech, Inc. | First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer |
| CN121045388A (zh) * | 2024-05-30 | 2025-12-02 | 英百瑞(杭州)生物医药有限公司 | 针对人c-Met和人EGFR的双特异性抗体及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2569409T3 (es) * | 2005-03-08 | 2016-05-10 | Pfizer Products Inc. | Composiciones de anticuerpo anti-CTLA-4 |
| MX361088B (es) * | 2012-11-21 | 2018-11-26 | Janssen Biotech Inc | Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos. |
| TW201922780A (zh) * | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
| JP2020535181A (ja) * | 2017-09-29 | 2020-12-03 | ヤンセン バイオテツク，インコーポレーテツド | 低用量抗体組成物を安定化する新規製剤 |
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
-
2021
- 2021-08-24 TW TW110131219A patent/TWI907491B/zh active
- 2021-08-24 AR ARP210102390A patent/AR123340A1/es unknown
- 2021-08-26 IL IL300895A patent/IL300895A/en unknown
- 2021-08-26 EP EP21860689.5A patent/EP4204456A4/en active Pending
- 2021-08-26 CR CR20230102A patent/CR20230102A/es unknown
- 2021-08-26 JP JP2023513278A patent/JP2023540025A/ja active Pending
- 2021-08-26 WO PCT/IB2021/057802 patent/WO2022043900A1/en not_active Ceased
- 2021-08-26 KR KR1020237009728A patent/KR20230057400A/ko active Pending
- 2021-08-26 CA CA3192630A patent/CA3192630A1/en active Pending
- 2021-08-26 MX MX2023002367A patent/MX2023002367A/es unknown
- 2021-08-26 PE PE2023000717A patent/PE20231370A1/es unknown
- 2021-08-26 AU AU2021333882A patent/AU2021333882A1/en active Pending
- 2021-08-26 CN CN202180052293.6A patent/CN116194485A/zh active Pending
- 2021-08-26 US US17/412,346 patent/US20220064307A1/en active Pending
- 2021-08-26 BR BR112023003373A patent/BR112023003373A2/pt unknown
- 2021-11-15 AR ARP210103156A patent/AR124067A2/es unknown
-
2023
- 2023-02-23 JO JOJO/P/2023/0040A patent/JOP20230040A1/ar unknown
- 2023-02-24 EC ECSENADI202313655A patent/ECSP23013655A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3192630A1 (en) | 2022-03-03 |
| AU2021333882A1 (en) | 2023-05-11 |
| CN116194485A (zh) | 2023-05-30 |
| ECSP23013655A (es) | 2023-03-31 |
| AR124067A2 (es) | 2023-02-08 |
| EP4204456A1 (en) | 2023-07-05 |
| KR20230057400A (ko) | 2023-04-28 |
| WO2022043900A1 (en) | 2022-03-03 |
| AR123340A1 (es) | 2022-11-23 |
| PE20231370A1 (es) | 2023-09-07 |
| IL300895A (en) | 2023-04-01 |
| TWI907491B (zh) | 2025-12-11 |
| US20220064307A1 (en) | 2022-03-03 |
| JP2023540025A (ja) | 2023-09-21 |
| MX2023002367A (es) | 2023-05-22 |
| AU2021333882A9 (en) | 2023-07-13 |
| EP4204456A4 (en) | 2024-09-04 |
| BR112023003373A2 (pt) | 2023-04-11 |
| CR20230102A (es) | 2023-06-23 |
| TW202227129A (zh) | 2022-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230040A1 (ar) | تركيبات مستقرة تتألف من جسم مضاد egfr/c-met ثنائي النوعية | |
| PH12023552883A1 (en) | High concentration bispecific antibody formulations | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| ZA202001564B (en) | Anti- folate receptor alpha antibody conjugates and their uses | |
| MX2024005727A (es) | Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3. | |
| CY1120342T1 (el) | Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου | |
| CY1120670T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi) | |
| CL2019002270A1 (es) | Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527) | |
| JOP20220070A1 (ar) | مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها | |
| JOP20210323A1 (ar) | ارتباط أجسام مضادة ثقيلة السلسلة ومتعددة النوعية بـ cd22 وcd3 | |
| CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
| RU2018140960A (ru) | Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4 | |
| JP2015520143A5 (https=) | ||
| MX2024005831A (es) | Conjugado de anticuerpo biespecifico-farmaco de camptotecina y uso farmaceutico del mismo. | |
| MX2024015884A (es) | Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1, y metodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1 | |
| AR110424A1 (es) | Moléculas de unión a adam9 y métodos de uso de las mismas | |
| CL2024001384A1 (es) | Moleculas de anticuerpo y conjugados | |
| UY39517A (es) | Inhibidores de la btk | |
| EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
| JOP20220193A1 (ar) | صياغات من الأجسام المضادة لـ tslp البشرية وطرق لاستخدامها | |
| BR112021008774A2 (pt) | Formulação farmacêutica, agente de ligação, métodos para tratamento de uma doença, para produzir uma formulação farmacêutica, para induzir a morte celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, uso de uma formulação farmacêutica | |
| BR112022020482A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri | |
| CL2024001635A1 (es) | Compuestos de diazaspiro sustituidos con carbonilo y su uso | |
| MX2020002266A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos. | |
| AR122060A1 (es) | Formulaciones de anticuerpos anti-il-33 y métodos de uso de las mismas |